The U.S. Food and Drug Administration (FDA) granted initial approval for the generic combination product Dapagliflozin And Metformin Hydrochloride (ANDA 211579) on 2026-04-06. This approval, sponsored by LUPIN, introduces a new generic option for a widely used therapy.
Background
This approval specifically concerns an Abbreviated New Drug Application (ANDA), which allows for the marketing of a generic drug product. An ANDA demonstrates that the generic drug is bioequivalent to its reference listed drug (RLD), meaning it performs in the same way as the original brand-name product. Generic drugs like Dapagliflozin And Metformin Hydrochloride are rigorously reviewed by the FDA to ensure they meet the same high standards for quality, strength, purity, and stability. The product combines dapagliflozin and metformin hydrochloride as its active ingredients.
What this means
The FDA's approval of LUPIN's generic Dapagliflozin And Metformin Hydrochloride is a significant development for patients and healthcare providers. Generic approvals typically lead to increased market competition, which can result in more affordable treatment options and improved access for patients requiring this combination therapy. By providing a bioequivalent alternative, this approval helps ensure that essential medications remain accessible and cost-effective within the healthcare system, potentially benefiting a broader patient population.
Source
The information regarding this initial approval was obtained from the official U.S. Food and Drug Administration (FDA) website. The approval for Abbreviated New Drug Application (ANDA) 211579 was recorded on 2026-04-06 and is publicly accessible via accessdata.fda.gov.